Susquehanna International Group’s Atea Pharmaceuticals AVIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $592K | Buy |
164,522
+58,938
| +56% | +$212K | ﹤0.01% | 4091 |
|
|
2025
Q1 | $316K | Buy |
105,584
+54,027
| +105% | +$162K | ﹤0.01% | 4965 |
|
|
2024
Q4 | $173K | Sell |
51,557
-1,611
| -3% | -$5.4K | ﹤0.01% | 5405 |
|
|
2024
Q3 | $178K | Sell |
53,168
-14,378
| -21% | -$48.2K | ﹤0.01% | 4873 |
|
|
2024
Q2 | $224K | Sell |
67,546
-117,865
| -64% | -$390K | ﹤0.01% | 4596 |
|
|
2024
Q1 | $749K | Buy |
185,411
+132,067
| +248% | +$534K | ﹤0.01% | 2999 |
|
|
2023
Q4 | $163K | Sell |
53,344
-164,530
| -76% | -$502K | ﹤0.01% | 5113 |
|
|
2023
Q3 | $654K | Sell |
217,874
-87,411
| -29% | -$262K | ﹤0.01% | 3064 |
|
|
2023
Q2 | $1.14M | Buy |
305,285
+119,828
| +65% | +$448K | ﹤0.01% | 2535 |
|
|
2023
Q1 | $621K | Buy |
185,457
+152,753
| +467% | +$512K | ﹤0.01% | 3530 |
|
|
2022
Q4 | $157K | Buy |
32,704
+11,484
| +54% | +$55.2K | ﹤0.01% | 4660 |
|
|
2022
Q3 | $121K | Sell |
21,220
-27,196
| -56% | -$155K | ﹤0.01% | 5160 |
|
|
2022
Q2 | $344K | Buy |
48,416
+5,807
| +14% | +$41.3K | ﹤0.01% | 3811 |
|
|
2022
Q1 | $308K | Buy |
42,609
+31,597
| +287% | +$228K | ﹤0.01% | 4316 |
|
|
2021
Q4 | $98K | Sell |
11,012
-67,325
| -86% | -$599K | ﹤0.01% | 5304 |
|
|
2021
Q3 | $2.75M | Buy |
78,337
+62,837
| +405% | +$2.2M | ﹤0.01% | 1649 |
|
|
2021
Q2 | $333K | Buy |
+15,500
| New | +$333K | ﹤0.01% | 4343 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 5168 |
|